Corbus Pharmaceuticals (NASDAQ:CRBP) Given New $56.00 Price Target at Oppenheimer
Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its target price reduced by Oppenheimer from $60.00 to $56.00 in a research report released on Wednesday,Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. CRBP has been the topic of several other reports. Jefferies Financial Group lowered their price target on shares of […]
More Stories
House Passes DHS Funding Bill Amid Shutdown
By Jackson Richman and Nathan Worcester WASHINGTON—The House of Representatives passed a bill to fund the Department of Homeland Security...
Unemployment Claims Signal Labor Market Stabilization Ahead of Jobs Report
By Andrew Moran The number of Americans filing applications for state unemployment benefits was flat ahead of tomorrow’s highly anticipated...
More Than 20 States Sue Over Trump’s New Global Tariffs
By Matthew Vadum More than 20 states filed a lawsuit on March 5 in federal court against President Donald Trump’s...
At Least 9 Vessels Attacked in Gulf Since Iran War Began
By Owen Evans At least nine vessels have come under attack since the U.S.–Israel military operation against Iran began on...
Hegseth Signs Joint Declaration to Boost Counter-Cartel Efforts in Western Hemisphere
By Ryan Morgan DORAL, Florida.—U.S. Secretary of War Pete Hegseth joined military officials from across Latin America and the Caribbean...
Typical US Homeowners Stay 12 Years in Their Homes—20 Years in Los Angeles
By Mary Prenon U.S. homeowners stayed in their houses for about 12 years as of 2025—the longest median time since...